Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial

ENGLEWOOD, Colo., Aug. 18, 2014 -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 6 weeks results of the open label portion of the multiple injections of Ampion™ into the knees of patients (n=7) with osteoarthritis (OA).

Vaughan Clift, MD, Ampio's Chief Regulatory Officer explained: "This first part of the multiple injection study involved patients receiving a series of three 4ml injections of Ampion™ intra-articularly (at baseline, 2 weeks and four weeks). In order to proceed with the randomized vehicle- controlled portion of the trial, which is now being expanded to multiple sites across the US, we had to demonstrate safety and efficacy of three injections compared to a single injection demonstrated previously in the SPRING study. There were no drug related serious adverse events reported during the first 6 weeks of this current trial."

Published: 18 August 2014

Written by Editor

AMEX Up on News Project Update

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Achillion to Begin a Six Week Treatment Regimen With Its Second-Generation NS5A Inhibitor ACH-3102 and Sofosbuvir

NEW HAVEN, Conn., Aug. 15, 2014 -- Achillion Pharmaceuticals, Inc. (ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naive genotype 1 chronic hepatitis C virus (HCV) infection. Of the 12 patients treated, 100 percent (n=12/12) remained HCV RNA undetectable four weeks after completing therapy (SVR4). Based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir.

Published: 15 August 2014

Written by Editor

Nasdaq Project Update

RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering

ST. LOUIS & SAN DIEGO -- Otonomy, a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering.

The San Diego-based biopharma company priced 6.25 million shares of common stock at a price of $16.00 per share, which starts trading today on the NASDAQ under the symbol OTIC.

Otonomy also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock which could increase the gross offering to a maximum of $115 million if exercised. Otonomy is expected to have an opening market capitalization of approximately $350 million.

Published: 13 August 2014

Written by Editor

Nasdaq Up on News New Listing

BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)

ALAMEDA, Calif.-- BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device. Premvia™is the first FDA-cleared member of BioTime’s HyStem^® family of hydrogels, which are designed to mimic the natural structures of the human body’s extracellular matrix. According to the FDA clearance, the product is indicated for the management of wounds including: partial thickness, full-thickness, tunneling wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, donor skin graft sites, post-Moh’s surgery, post-laser surgery, podiatric wounds, wound dehiscence, abrasions, lacerations, second degree burns, skin tears and draining wounds.

Published: 12 August 2014

Written by Editor

AMEX FDA HC Decision Up on News

Intercept Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business Update

NEW YORK, Aug. 11, 2014 -- Intercept Pharmaceuticals, Inc. (ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today reported financial results for the quarter and six months ended June 30, 2014 and provided other general business updates including additional data from the FLINT trial in NASH patients. These results are included in Intercept's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission. Intercept will hold a conference call and audio webcast today at 4:30 p.m. ET to review this information with conference call details provided below.

Published: 12 August 2014

Written by Editor

Nasdaq Financial Results

Page 190 of 246

Ampio Pharmaceuticals Inc ( AMPE )

Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial

Achillion Pharmaceuticals Inc ( ACHN )

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Otonomy Inc ( OTIC )

RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering

BioTime Inc ( BTX )

BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)

Intercept Pharmaceuticals Inc ( ICPT )

Intercept Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business Update